Retatrutide and Sleep Apnea (Obstructive Sleep Apnea)

Obstructive sleep apnea (OSA) is one of the most common and underdiagnosed consequences of obesity. It occurs when excess tissue in the upper airway collapses during sleep, causing repeated breathing interruptions. OSA affects an estimated 30-40% of adults with obesity, worsens cardiovascular risk, impairs quality of life, and increases daytime fatigue and mortality.

Weight loss is the single most effective non-surgical intervention for OSA. Every 1% of body weight lost is associated with an approximate 3% reduction in the apnea-hypopnea index (AHI), the primary measure of sleep apnea severity. Given that retatrutide has demonstrated weight loss of up to 28.7% in Phase 3 trials, its potential impact on OSA is substantial.

No retatrutide-specific OSA data has been published yet. The TRIUMPH-1 Phase 3 trial includes a nested OSA sub-study, with results expected in 2026. This page covers what we know, what we expect, and the relevant precedent from tirzepatide's OSA trial.

Retatrutide is an investigational drug that has not been approved by the FDA.

The TRIUMPH-1 OSA Sub-Study

Trial design

The pivotal TRIUMPH-1 Phase 3 trial is structured as a basket trial with nested protocols for multiple conditions, including obstructive sleep apnea. A trial design paper was published in Diabetes, Obesity and Metabolism in October 2025.

The nested design means that participants who have both obesity and diagnosed OSA will have their sleep apnea metrics tracked as part of the larger trial. This is an efficient approach — it generates OSA-specific data without requiring a separate standalone trial.

What we expect to learn

• AHI reduction — the primary measure of how many times per hour breathing stops or significantly decreases during sleep
• Shift in OSA severity — whether participants move from severe to moderate, moderate to mild, or achieve full resolution
• CPAP use — whether weight loss on retatrutide allows patients to discontinue continuous positive airway pressure (CPAP) therapy
• Sleep quality metrics — patient-reported outcomes on daytime sleepiness and sleep quality

Why Weight Loss Improves Sleep Apnea

OSA is fundamentally a mechanical problem: excess fat deposits around the upper airway — particularly in the neck, tongue, and pharynx — narrow the airway. During sleep, when muscle tone decreases, this narrowed airway is more likely to collapse.

Weight loss reduces these fat deposits, widening the airway and reducing the frequency and severity of obstructive events. The relationship is well-established:

• 10% weight loss typically produces a ~26% reduction in AHI
• 15-20% weight loss can move many patients from severe to mild OSA, or from mild to resolution
• Bariatric surgery (which produces 20-30% weight loss) has been shown to resolve OSA in a significant proportion of patients

Retatrutide's 28.7% mean weight loss at the 12mg dose in TRIUMPH-4 is in the range typically associated with substantial OSA improvement or resolution.

Precedent: Tirzepatide's SURMOUNT-OSA Trial

The most direct precedent for a GLP-1 class drug treating OSA comes from tirzepatide's SURMOUNT-OSA trial, results of which were published in 2024.

SURMOUNT-OSA key results

The SURMOUNT-OSA results were strong enough that Eli Lilly submitted tirzepatide for an OSA-specific indication, and the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in 2024. This was the first drug approved specifically for sleep apnea.

What this means for retatrutide

SURMOUNT-OSA establishes two important precedents:

1. The FDA will approve a weight loss drug for an OSA indication — this is no longer hypothetical
2. The relationship between weight loss and AHI reduction is consistent and predictable — if retatrutide produces greater weight loss than tirzepatide, it is reasonable to expect at least comparable (and potentially greater) OSA improvement

Lilly has confirmed that it plans to submit retatrutide data supporting an OSA indication as part of its regulatory filings.

Understanding Sleep Apnea Severity

The Apnea-Hypopnea Index (AHI)

AHI measures the number of apneas (complete breathing cessations) and hypopneas (partial breathing reductions) per hour of sleep. It is the standard metric for diagnosing and grading OSA.

Why AHI reduction matters

Reducing AHI translates directly to fewer breathing interruptions per night. This improves:

• Oxygen saturation — fewer episodes of low blood oxygen during sleep
• Sleep architecture — fewer arousals means more restorative deep sleep
• Daytime function — reduced fatigue, improved concentration, lower accident risk
• Cardiovascular risk — untreated severe OSA is associated with increased risk of hypertension, atrial fibrillation, heart failure, and stroke

The Broader TRIUMPH OSA Strategy

OSA sub-studies are nested within both TRIUMPH-1 and TRIUMPH-2 (the T2D obesity trial). This dual-population approach means Lilly will have OSA data in:

• Patients with obesity without diabetes (TRIUMPH-1)
• Patients with obesity and type 2 diabetes (TRIUMPH-2)

Both populations have high OSA prevalence, and having data in both strengthens the case for a broad OSA indication.

Current Treatment Options for OSA

While waiting for retatrutide, people with OSA have several established treatment options:

CPAP therapy

Continuous positive airway pressure remains the gold standard for OSA treatment. It is highly effective but has well-documented adherence challenges — many patients find the mask uncomfortable and do not use it consistently.

Tirzepatide (Zepbound)

As of 2024, tirzepatide is the first and only drug specifically approved for moderate-to-severe OSA in adults with obesity. It is available by prescription now and represents a pharmaceutical alternative or complement to CPAP.

Weight loss (any method)

Any form of sustained weight loss — lifestyle changes, other medications, bariatric surgery — can improve OSA. The magnitude of improvement correlates with the amount of weight lost.

Oral appliances and surgery

Mandibular advancement devices and surgical interventions (such as uvulopalatopharyngoplasty) are options for some patients, particularly those who cannot tolerate CPAP or are not candidates for weight loss medications.

Frequently Asked Questions

Sources

• TRIUMPH trial design paper. Diabetes, Obesity and Metabolism. October 2025. DOI: 10.1111/dom.70209
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• Malhotra, A., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.
• ClinicalTrials.gov: Retatrutide trials

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

If you have symptoms of sleep apnea — loud snoring, witnessed breathing pauses, excessive daytime sleepiness — talk to your doctor about diagnosis and treatment with currently available options. Do not delay treatment while waiting for an unapproved drug.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.